Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03775486
Title Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors AstraZeneca
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Olaparib

Cisplatin + Durvalumab + Pemetrexed Disodium

Durvalumab

Carboplatin + Durvalumab + Gemcitabine

Carboplatin + Durvalumab + Pemetrexed Disodium

Carboplatin + Durvalumab + Nab-paclitaxel

Cisplatin + Durvalumab + Gemcitabine

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST